Gout

You have full text access to this OnlineOpen article

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial†‡

  1. H. RALPH Schumacher Jr.1,§,*,
  2. Michael A. Becker2,¶,
  3. Robert L. Wortmann3,‖,
  4. Patricia A. MacDonald4,
  5. Barbara Hunt4,
  6. Janet Streit4,
  7. Christopher Lademacher4,
  8. Nancy Joseph-Ridge4,††

Article first published online: 30 OCT 2008

DOI: 10.1002/art.24209

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 59, Issue 11, pages 1540–1548, 15 November 2008

Additional Information

How to Cite

Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C. and Joseph-Ridge, N. (2008), Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis & Rheumatism, 59: 1540–1548. doi: 10.1002/art.24209

Author Information

  1. 1

    University of Pennsylvania and VA Medical Center, Philadelphia

  2. 2

    Pritzker School of Medicine, University of Chicago, Chicago, Illinois

  3. 3

    Dartmouth Medical School, Hanover, New Hampshire

  4. 4

    Takeda Global Research & Development Center, Inc., Deerfield, Illinois (of which TAP Pharmaceuticals, Inc., is now a subsidiary)

  1. §

    Dr. Schumacher has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Takeda Global Research & Development Center, Inc., and Savient.

  2. Dr. Becker has received consultant fees (more than $10,000) from Takeda Global Research & Development Center, Inc.

  3. ‖

    Dr. Wortmann has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Takeda Global Research & Development Center, Inc., and Merck & Company.

  4. ††

    Dr. Joseph-Ridge owns stock and/or holds stock options in Abbott Laboratories.

*VA Medical Center, 151K University and Woodland Avenues, Philadelphia, PA 19104

  1. †

    ClinicalTrials.gov identifier: NCT00174915.

  2. ‡

    Previously published in abstract form: Schumacher HR, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study [abstract]. Arthritis Rheum 2005;52 Suppl 9:S680.

Publication History

  1. Issue published online: 30 OCT 2008
  2. Article first published online: 30 OCT 2008
  3. Manuscript Accepted: 10 JUN 2008
  4. Manuscript Received: 20 DEC 2007

Funded by

  • Takeda Global Research & Development Center, Inc., Deerfield, Illinois
  • Takeda Global Research & Development Center, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

REFERENCES

  • 1
    Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445–51.
  • 2
    Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312–24.
  • 3
    Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999; 59: 925–34.
  • 4
    Hershfield MS. Gout and uric acid metabolism. In: GoldmanL, BennettJC, editors. Cecil textbook of medicine. 21st ed. Philadelphia: WB Saunders; 2000. p. 1541–8.
  • 5
    Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577–80.
  • 6
    Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15: 189–92.
    Direct Link:
  • 7
    Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19: 122–7.
  • 8
    Terkeltaub RA. Clinical practice: gout. N Engl J Med 2003; 349: 1647–55.
  • 9
    Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005; 17: 319–24.
  • 10
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61.
  • 11
    Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12: 61–5.
  • 12
    Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321–5.
    Direct Link:
  • 13
    Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13–8.
  • 14
    Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356–60.
    Direct Link:
  • 15
    Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52: 916–23.
    Direct Link:
  • 16
    Choy G. An update on the treatment options for gout and calcium pyrophosphate deposition. Expert Opin Pharmacother 2005; 6: 2443–53.
  • 17
    Keith MP, Gilliland WR. Updates in the management of gout. Am J Med 2007; 120: 221–4.
  • 18
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337–43.
  • 19
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47–56.
  • 20
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82–7.
    Direct Link:
  • 21
    Allopurinol tablets, USP [package insert]. Spring Valley (NY): Par Pharmaceutical; 2001.
  • 22
    Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [abstract]. Arthritis Res Ther 2006; 8 Suppl 1: S4.
  • 23
    Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 1848–55.
  • 24
    Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005; 76: 1835–47.
  • 25
    Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, et al. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 2000; 60: 34–40.
  • 26
    Grabowski BA, Vernillet L, Khosravan R, Wu J, Joseph-Ridge N, Mulford DJ. Absorption, metabolism and excretion of [14C]febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in healthy male subjects [abstract]. Drug Metab Rev 2005; 37: 111.
  • 27
    Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1111–6.
  • 28
    Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006; 45: 821–41.
  • 29
    Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1119–22.
  • 30
    Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1117–8.
  • 31
    Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005; 12: 22–34.
  • 32
    Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900.
    Direct Link:
  • 33
    Schumacher HR, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005; 32: 2368–72.
  • 34
    Hochberg Y. A sharper Bonferroni procedure for multiple test of significance. Biometrika 1988; 75: 800–2.
  • 35
    Brewis I, Ellis RM, Scott JT. Single daily dose of allopurinol. Ann Rheum Dis 1975; 34: 256–9.
  • 36
    Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545–9.
  • 37
    Rodnan GP, Robin JA, Tolchin SF, Elion GB. Allopurinol and gouty hyperuricemia: efficacy of a single daily dose. JAMA 1975; 231: 1143–7.
  • 38
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229–58.
  • 39
    Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646–50.
  • 40
    Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981–3.
  • 41
    Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology (Oxford) 2006; 45: 1422–31.
View Full Article (HTML) Get PDF (152K)